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Abstract. Epidemiological data indicate that the daily 
consumption of extra‑virgin olive oil (EVOO), a common 
dietary habit of the Mediterranean area, lowers the incidence 
of certain types of cancer, in particular bladder neoplasm. The 
aim of the present study was to evaluate the antiproliferative 
activity of polyphenols extracted from EVOO on bladder 
cancer (BCa), and to clarify the biological mechanisms that 
trigger cell death. Furthermore, we also evaluated the ability 
of low doses of extra‑virgin olive oil extract (EVOOE) to 
modulate the in vitro activity of paclitaxel or mitomycin, two 
antineoplastic drugs used in the management of different 
types of cancer. Our results showed that EVOOE significantly 
inhibited the proliferation and clonogenic ability of T24 and 
5637 BCa cells in a dose‑dependent manner. Furthermore, 
cell cycle analysis after EVOOE treatment showed a marked 
growth arrest prior to mitosis in the G2/M phase for both cell 
lines, with the subsequent induction of apoptosis only in the 
T24 cells. Notably, simultaneous treatment of mitomycin C 
and EVOOE reduced the drug cytotoxicity due to inhibition 
of ROS production. Conversely, the co‑treatment of T24 cells 
with paclitaxel and the polyphenol extract strongly increased 
the apoptotic cell death at each tested concentration compared 
to paclitaxel alone. Our results support the epidemiological 
evidence indicating that olive oil consumption exerts health 
benefits and may represent a starting point for the development 
of new anticancer strategies.
Introduction
Bladder cancer (BCa) is one of the most common cancers in 
Western countries and the first leading cause of death among 
urinary malignancies (1). The incidence and mortality rates 
of BCa vary substantially across countries, in part due to 
different risk factors. In 2007, a comprehensive review by the 
World Cancer Research Fund and the American Institute for 
Cancer Research concluded that established risk factors for 
BCa include tobacco consumption, Schistosoma haematobium 
infection, and both occupational and environmental expo‑
sure to carcinogens such as aromatic amines and polycyclic 
aromatic hydrocarbons and arsenic in drinking water (2).
The role of nutrition as a protective factor in the devel‑
opment of BCa remains unclear but many data indicate that 
a regular consumption of fruit and vegetables appears to be 
linked to a lower incidence of urothelial neoplasia (3). A 
recent study in a multiethnic cohort showed that the intake 
of vegetables and some related micronutrients such as vita‑
mins A, C, E and carotenoids was inversely associated with 
BCa risk only in women (4). Ros et al showed that a higher 
plasma carotenoid concentration was associated with a lower 
incidence of BCa, suggesting that specific compounds in fruit 
and vegetables may exert protective effects on BCa risk (5). 
Moreover, data of the European Prospective Investigation into 
Cancer and Nutrition (EPIC) study, found an inverse associa‑
tion between the dietary intake of flavanols and lignans and 
the risk of BCa (6).
Epidemiological evidence and many case‑control studies 
strongly support the hypothesis that adherence to the 
Mediterranean diet reduces cancer risk and in particular olive 
oil consumption is inversely related to cancer prevalence (7,8). 
Olive oil is the main dietary fat of the Mediterranean area and 
its health‑promoting properties are well assessed by numerous 
studies (9‑12). Historically, the beneficial effects of olive 
oil intake have been attributed to the high concentration of 
monounsaturated fatty acids (MUFAs) such as oleic acid that 
represents the main component. However, other oils rich in 
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MUFA, derived from the seeds of soybean or rapeseed, do not 
exert the same health benefits as extra‑virgin olive oil (EVOO). 
In the last few years, attention has been focused on the minor 
phenolic fraction mainly constituted of a complex mixture 
comprising at least 36 distinct compounds (10). The most 
represented phenolic molecules in EVOO are secoiridoids, 
such as oleuropein and ligstroside, and phenolic alcohols, 
such as hydroxytyrosol (HTy) and tyrosol (TY), accounting 
for ~90% of total phenols. The remaining 10% of the mixture 
is mainly constituted by flavonoids and lignans. Polyphenols 
have well‑known antioxidant, anti‑inflammatory, cardiopro‑
tective, anti‑atherogenic, antithrombotic, neuroprotective and 
anticancer activities (13‑15). Recent findings suggest that in 
low amounts, polyphenols may exert pharmacological activity 
within cells. In particular, polyphenols have the potential to 
modulate intracellular signaling cascades, to affect gene 
expression, to interact with mitochondria and to induce 
antioxidant enzymes as well as to inhibit the expression of 
enzymes involved in the generation of free radicals (16). By 
affecting such pathways they have the ability to control cell 
survival, death and differentiation, and to exhibit marked 
anti‑inflammatory activity via modulation of the expres‑
sion of pro‑inflammatory genes mainly acting through 
nuclear factor‑κB and mitogen‑activated protein kinase 
signaling (17,18). Owing to all of these properties, polyphenols 
exert anticancer effects through the modulation of genes and 
molecular signaling pathways associated with cell survival, 
cell cycle progression, cell growth arrest and apoptosis, as 
demonstrated in several tumor cell lines (19).
In a previous study, we demonstrated that very low doses of 
EVOO phenols inhibited the invasive ability of a BCa cell line 
by modulating the expression of MMP2 (20). The aim of the 
present study was to investigate the antiproliferative activity 
of extra‑virgin olive oil extract (EVOOE) on BCa, with the 
attempt to clarify the biological mechanisms that trigger cell 
death. Moreover, we also evaluated the ability of low doses of 
EVOOE to modulate the in vitro activity of paclitaxel or mito‑
mycin C, two antineoplastic drugs used in the management of 
different types of cancer.
Materials and methods
Materials. Acetonitrile (CH3CN), n‑hexane, dimethyl‑
sulphoxide (DMSO), acetic acid, methanol, 3‑(4,5‑dimethyl‑
thiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide (MTT), pacli‑
taxel, mitomycin C and propidium iodide (PI) were purchased 
from Sigma‑Aldrich (St. Louis, MO, USA). T24 and 5637 
BCa cell lines were purchased from CLS Cell Lines Service 
GmbH (Eppelheim, Germany). All media and sera for cell 
culture were obtained from Invitrogen (Carlsbad, CA, USA) 
and were endotoxin‑free. 2',7'‑Dichlorodihydrofluorescein 
diacetate (H2DCFDA) was from Molecular Probes, 
Inc. (Eugene, OR, USA). For the immunofluorescence 
experiment, anti‑α‑tubulin antibody, TRITC‑labeled phal‑
loidin and anti‑mouse FITC‑conjugated secondary antibody 
were purchased from Sigma‑Aldrich (cat. nos. t5168, p1951 
and f0257, respectively). Protease inhibitor cocktail was 
purchased from Sigma‑Aldrich (cat. no. 11873580001) while 
Bradford reagent, Any kD™ polyacrylamide gel, anti‑mouse 
and anti‑rabbit secondary peroxidase‑conjugated antibodies 
were obtained from Bio‑Rad Laboratories, Inc. (Hercules, CA, 
USA) (cat. nos. 1706515 and 1706516, respectively). Primary 
antibodies for PARP‑1 and GAPDH were obtained from 
Cell Signaling Technology, Inc. (Danvers, MA, USA) (cat. 
nos. 9542 and 2118, respectively), caspase‑3 was from Santa 
Cruz Biotechnology, Inc. (Dallas, TX, USA) (cat. no. sc‑7148), 
and caspase‑9 was from Sigma‑Aldrich (cat. no. c7729).
Extraction of the olive oil phenolic fraction. EVOOE was 
obtained as previously described (21) with minor modifica‑
tions, from three different lots of an endemic monocultivar 
olive oil (Olea europaea L. var. Itrana) within 1 month after 
production. Fifty milliliters of each oil sample was extracted 
with 150 ml of CH3CN/H2O (70:30 v/v). A defatting with 
n‑hexane was performed to completely remove the lipid 
fraction. Aliquots of the raw hydrophilic extract were dried 
by SpeedVac and stored at ‑80˚C until use. The extract was 
dissolved in DMSO at a stock concentration of 10 mg/ml 
immediately before performing the experiments.
HPLC analysis of the phenolic fraction. The HPLC analysis 
of the extract was carried out with a Waters apparatus, 
equipped with a 600 F pump and pump controller, a Rheodyne 
injection valve with a 50‑µl loop, a Symmetry300 column 
(C18 reversed‑phase column, 4.6x250 mm, 5‑µm particle 
size, thermostated at 25˚C, with a 3.9x20 mm guard column 
of the same material matrix), and a Waters 2996 Photodiode 
Array Detector. The elution was performed at a flow rate of 
1 ml/min, with solvent A being 2% acetic acid and solvent B 
being methanol. The gradient consisted of an initial 5% B for 
5 min, to 50% B in 35 min, 100% B in 10 min, 100% B for 
10 min. Samples were filtered through a 0.45‑µm cellulose 
syringe filter before injection. Elution was monitored at 
280 nm and peak identification was obtained by comparing 
retention times and spectral characteristics with those of 
authentic standards.
Cell cultures. T24 and 5637 cells (human urinary bladder 
carcinoma) were cultured in DMEM without phenol red 
supplemented with 10% FBS, 2 mM glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin.
Cell proliferation assays. Cell viability was assessed using 
the dye MTT. The assay is based on the ability of living cells 
to convert MTT into an insoluble purple‑colored formazan, 
whose amount is proportional to the number of living cells. 
Cells seeded in 96‑well plates at a density of 5,000 cells/well 
were exposed to different concentrations of EVOOE, paclitaxel 
or mitomycin C. After 24 h, the cells were treated with 20 µl of 
a 5 mg/ml solution of MTT in PBS and incubated at 37˚C for 
4 h. After discarding the medium, the formazan was extracted 
with DMSO, and absorbance was read at 570 nm with a refer‑
ence at 690 nm with a Tecan Sunrise™ microplate reader.
Colony‑forming ability. The cells were plated at a density 
of 20 cells/cm2 in tissue culture Petri dishes and exposed 
to various concentrations of EVOOE. Cells were grown for 
14 days with a medium renewal every 2 days. After 2 weeks 
the cells were fixed with ethanol, and stained with Giemsa 
stain to detect the colonies.
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Cell cycle analysis. Flow cytometric analysis of the cells was 
performed using an Accuri C6 flow cytometer (BD Biosciences, 
Oxford, UK). To analyze cell cycle distribution, the cells were 
initially treated with various concentrations of EVOOE for 
24 h, and were then collected by trypsinization, fixed in 75% 
absolute ethanol, washed in PBS, and resuspended in 1 ml of 
PBS containing 0.5 mg/ml of RNase A and 0.01 mg/ml of PI 
in the dark for 30 min at room temperature. The percentage 
of cells in the sub‑G1, G0/G1, S, and G2/M phases of the cell 
cycle was analyzed using the ModFit LT 3.0 software (Verity 
Software House, Inc., Topsham, ME, USA).
Immunofluorescence staining of fibrous actin (F‑actin) and 
α‑tubulin. Cells were plated at a density of 2x104 cells/cm2 
on a glass coverslip. After 24 h, the media were removed and 
the cells were treated with media containing different doses 
of EVOOE for 4 h. After the incubation, the media were 
discarded and the glass coverslips were fixed for 20 min at 
‑20˚C in methanol. After fixation, the cells were rinsed three 
times with cold PBS and then permeabilized in PBS containing 
0.5% (v/v) Triton X‑100 for 5 min, blocked in bovine serum 
albumin (BSA) 5% (w/v) for 1 h and then incubated overnight 
at 4˚C with a human monoclonal anti‑α‑tubulin antibody 
produced in mouse diluted at 1:1,000 in PBS containing 0.2% 
(w/v) Triton X‑100. After incubation, the coverslips were 
rinsed three times in PBS and incubated for 45 min with a 
solution of TRITC‑labeled phalloidin which specifically binds 
to F‑actin and anti‑mouse FITC‑conjugated antibody. The 
cell nuclei were counterstained with DAPI and the specimens 
were mounted on glass slides. The images were captured with 
a Nikon ViCo.2 video confocal microscope (Nikon, Inc., 
Garden City, NY, USA) at a magnification of x600.
Measurement of intracellular ROS generation. Intracellular 
ROS levels were evaluated by treating cells with 2 µM 
H2DCFDA for 1 h at 37˚C in the presence of different doses 
of EVOOE. H2DCFDA, the acetylated form of 2',7'‑dichlo‑
rofluorescein (DCF), is not fluorescent until intracellular 
deacetylation and oxidation by peroxides (22). Fluorescent 
intensities were quantified by flow cytometry.
Western blot analysis. T24 and 5637 cells were seeded in 
10‑cm Petri plates at a concentration of 1x106 cells/plate. After 
24 h, the cells were treated with different concentrations of 
EVOOE for an additional 24 h. The cells were scraped in 
culture medium, washed twice with PBS, and finally lysed 
into 200 µl RIPA buffer [50 mM Tris, pH 8.0, 150 mM NaCl, 
1% NP‑40, 0.5% Na‑deoxycholate, and 0.1% sodium dodecyl 
sulfate (SDS)], containing a protease inhibitor cocktail. After 
20 min on ice, the lysates were centrifuged at 20,000 x g 
for 10 min. Protein concentration was determined with the 
Bradford reagent. The lysates (20 µg of the total protein) were 
resolved on Any kD™ polyacrylamide gel and transferred 
onto PVDF membranes. Membranes were blocked for 1 h 
with 5% BSA, dissolved in Tris‑buffered saline (TBS) solution 
(10 mM Tris‑HCl, pH 7.5, 150 mM NaCl). Membranes were 
then successively incubated overnight at 4˚C with primary 
human antibodies in TBST (TBS with 0.1% Tween‑20) with 
5% BSA at the following dilution: PARP‑1 1:1,000, caspase‑9, 
caspase‑3 1:500 and GAPDH 1:4,000. After washing in TBST 
solution, the secondary antibody [anti‑rabbit or anti‑mouse 
IgG horseradish peroxidase (HRP)‑conjugated antibody], 
diluted at 1:10,000 in TBST/5% BSA, was added for 50 min 
at room temperature. Signals were visualized by ECL reagent 
according to the manufacturer's instructions.
Statistics. Each assay was replicated at least four times, 
and statistical significance was determined using GraphPad 
Prism 4 statistical software package (GraphPad Software, Inc., 
San Diego, CA, USA). Data are expressed as means ± SD. 
Comparison of the groups was carried out by one‑way ANOVA 
followed by Bonferroni's post hoc test. Statistical significance 
was defined as P<0.05.
Results
EVOOE chromatographic analysis. EVOOE was analyzed by 
HPLC‑DAD to identify the main phenolic compounds present 
in the extract. Analyses revealed a chromatographic profile 
strictly similar to the one previously obtained for the same 
olive oil extraction (20) which was characterized by a large 
amount of secoiridoids such as the dialdehydic form of elenolic 
acid linked to TY (p‑HPEA‑EDA; oleocanthal) and the dialde‑
hydic form of elenolic acid linked to HTy (3,4‑DHPEA‑EDA; 
oleuropein aglycon, dialdehydic form), and of lignans such as 
pinoresinol, whereas the simple phenolic fraction was scarcely 
represented, with very low amounts of TY, HTy, vanillic acid, 
vanillin, p‑coumaric and ferulic acids. The low content of 
simple phenols such as TY and HTy indicates that the olive 
oil samples were obtained by correct production procedures 
giving rise to a high quality EVOO (20).
EVOOE inhibits cell growth and clonogenic survival. The 
cytotoxic effect of EVOOE on BCa cells was evaluated by 
MTT assay after 24 h of exposure to the phenolic extract. 
As shown in Fig. 1A, EVOOE treatment decreased T24 cell 
viability in a dose‑dependent manner with growth inhibition 
ranging from 40 to ~90%, at 25 and 100 µg/ml, respectively 
and an IC50 of 32±3 µg/ml. The viability of 5637 cells was 
also inhibited by the treatment in a dose‑dependent manner 
with a higher IC50 of 55±7 µg/ml. Proliferation of neither of 
the two cell lines was affected at doses <10 µg/ml up to 72 h 
(data not shown).
We also examined the effect of EVOOE at subtoxic doses 
on the clonogenic survival of T24 and 5637 cells. This assay 
determines the ability of a cell to proliferate indefinitely, 
retaining its reproductive ability to form a large colony or 
a clone. Importantly, both cell lines showed a significant 
decrease (P<0.001) in the ability to form colonies starting 
at a dose of 5 µg/ml with a marked inhibition of clonogenic 
activity at 10 µg/ml (Fig. 1B).
EVOOE blocks the cell cycle progression at G2/M stage. To 
better understand the mechanism underlying the cell growth 
impairment by EVOOE, cell cycle progression was investi‑
gated. T24 and 5637 cells were treated with increasing doses 
of EVOOE, and cell cycle distribution analysis was then 
performed after 24 h of exposure. As shown in Table I, the 
G2/M population of the EVOOE‑treated T24 cells increased 
from 11.1% of the control to ~27% at EVOOE doses of 
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20 and 40 µg/ml. The treatment also induced a marked decrease 
in the G0/G1 population in a dose‑dependent manner with a 
subsequent increase in sub‑G1 particles (Fig. 2). This result 
revealed that EVOOE treatment caused marked accumulation 
of the G2/M population in the T24 cells that led to an accumu‑
lation of the sub‑G1 fraction probably indicating induction of 
apoptosis. The cell cycle analysis of 5637 cells after EVOOE 
treatment revealed a similar behavior to that observed for the 
T24 cells, but with a consistently larger increase in the G2/M 
population at 40 µg/ml (28% of T24 vs. 44% of 5637 cells). 
Notably, no increase in the sub‑G1 fraction was observed for 
this cell line.
Table I. Percentage of cells in each phase of the cell cycle after 24 h of treatment with various doses of EVOOE.a
 T24 cells 5637 cells
EVOOE ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
(µg/ml) 0 10 20 40 0 10 20 40
Sub‑G1 6±2 8±0.5 18±0.3b 28±3b 3±0.4 2±0.5 4±1 5±1
G1 72±4 70±6 41±4b 30±2b 60±5 64±6 59±5 34±2b
S 12±3 10±3 16±4 14±1 24±1 22±3 16±0.7 17±3
G2/M 10±1 12±4 25±2b 28±4b 13±2 12±0.7 21±0.8b 44±3b
aThe data represent the mean percentage of cells ± SEM and are calculated from three independent experiments. bP<0.01 compared to untreated 
control. EVOOE, extra‑virgin olive oil extract.
Figure 1. EVOOE inhibits cell growth. (A) Dose‑response curve obtained with the MTT assay after 24 h of exposure to increasing doses of EVOOE. The data 
are presented as means ± SD. (B) Colony‑forming ability assay. After 14 days of exposure to low doses of EVOOE (≤10 µg/ml), the colony‑forming ability 
of both cell lines tested markedly decreased with a reduction in the number and dimension of the colony formed. The histogram represents the percentage of 
number of colonies formed after EVOOE treatment compared with the untreated control. The data are presented as means ± SD. EVOOE, extra‑virgin olive 
oil extract.
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Short‑time exposure to EVOOE alters cell morphology. 
Interestingly, a consistent change in cell morphology was 
noticeable in all the experiments performed. In order to explain 
this phenomenon, we tested the hypothesis that EVOOE could 
interfere with cytoskeleton remodeling and the subsequent 
mitotic process. After treatment with 20 and 40 µg/ml of 
EVOOE for 4 h, the cells acquired a rounded morphology. In 
order to verify the alteration of the cytoskeleton, we performed 
immunofluorescence experiments using phalloidin (that bind 
to F‑actin) and an antibody against α‑tubulin. As clearly 
visible from Fig. 3, the treatment induced a change in T24 cell 
morphology with a marked variation of cytoskeleton network 
arrangement and a perinuclear accumulation of α‑tubulin.
EVOOE induces apoptosis only in T24 cells. Despite the cell 
cycle blockade in the G2/M phase that occurred in both cell 
lines, cell cycle analysis revealed an accumulation of particles 
(sub‑G1) with a small content of DNA only in T24 cells (Fig. 2), 
indicating that only in this cell line did the onset of apoptotic 
processes occur. In order to confirm this finding, we performed 
western blot analysis of PARP‑1 and pro‑caspase‑3 and ‑9. 
Proteolytic cleavage of specific proteins such as PARP‑1 has 
been shown to occur in cells exposed to a number of apoptotic 
stimuli (23‑25). EVOOE was found to induce apoptotic cell 
Figure 2. EVOOE blocks cell cycle progression at G2/M stage. Distribution 
of T24 and 5637 cells in the different cell cycle compartments was analyzed 
by flow cytometry after 24 h in the absence or presence of various doses 
of EVOO phenolic extract following staining with PI. The panels show 
representative flow cytometry profiles obtained from three independent 
experiments. EVOOE, extra‑virgin olive oil extract.
Figure 3. EVOOE exposure alters T24‑cell morphology due to cytoskeleton remodelling. After 4 h of exposure to different EVOOE concentrations, the cells 
were subjected to immunofluorescence for F‑actin (red color) and α‑tubulin (green color) staining. The images shown are representative immunofluorescence 
staining of three independent experiments. Magnification, x600. EVOOE, extra‑virgin olive oil extract; F‑actin, fibrous actin.
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death only in T24 cells in a dose‑dependent manner. Indeed, 
western blot analysis (Fig. 4) of the cleavage of PARP‑1 
showed a decrease in the full‑size MW 116,000 fragment and 
an increase in the cleaved form within 24 h after the T24 cell 
treatment in a dose‑dependent manner (Fig. 4). Western blot 
analysis of caspase‑3 and ‑9 also showed a marked decrease in 
their protein levels at higher doses of the polyphenol extract. 
Conversely to what was observed for T24 cells, the treatment 
of 5637 cells did not induce apoptosis, as is clearly visible 
from Fig. 4 that shows the lack of any PARP‑1 cleavage.
EVOOE treatment decreases intracellular ROS produc‑
tion. The antioxidant effect of EVOOE was analyzed by 
determining intracellular ROS levels using cytofluorimetric 
analysis. After 1 h of treatment with different concentra‑
tions of EVOOE, the basal ROS production decreased in a 
dose‑dependent manner as clearly evidenced by the leftward 
shift of fluorescence that became greater at increasing doses 
of the polyphenol extract (Fig. 5). The data analysis revealed 
a decrease in the mean T24‑cell fluorescence ranging from 
12% at 10 µg/ml to 64% at 40 µg/ml. The same behavior was 
observed for the 5637 cells with a lesser antioxidant activity 
that became evident only at a dose of 40 µg/ml with a decrease 
in the mean cell fluorescence of 35%.
Figure 4. Western blot analysis of apoptosis‑related proteins. After 24 h of exposure to different doses of EVOOE, the cell samples were subjected to western 
blot analysis to assess the cleavage of PARP‑1 and of pro‑caspase‑3 and ‑9 protein levels. EVOOE, extra‑virgin olive oil extract.
Figure 5. EVOOE treatment reduces ROS production in both cell lines. 
After treatment with different concentrations of EVOOE, the cells were 
stained with DCF‑DA and analyzed by flow cytometry. The histograms 
represent the mean cell fluorescence which is directly related to ROS 
content. The straight line indicates the mean fluorescence of the untreated 
cells. The panels show representative flow cytometry profiles obtained from 
three independent experiments. EVOOE, extra‑virgin olive oil extract; DCF, 
2',7'‑dichlorofluorescein.
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EVOOE negatively affects mitomycin cytotoxicity. Mito‑
mycin C is a methylazirinopyrroloindoledione antineoplastic 
antibiotic isolated from the bacterium Streptomyces caespi‑
tosus and other Streptomyces bacterial species. Mitomycin C 
generates oxygen radicals, alkylates DNA, and produces 
interstrand DNA cross‑links, thereby inhibiting DNA 
synthesis. This drug is often used in the chemotherapy of 
BCa (26).
To evaluate the effect of the simultaneous exposure to the 
drug and EVOOE on cell viability, T24 cells were treated 
for 24 h with different doses of mitomycin in the presence 
or absence of the phenolic extract. In all the experiments, 
EVOOE was used at a dose of 10 µg/ml which was found to 
be non‑toxic.
The data shown in Fig. 6A demonstrated that, at each 
concentration tested, the simultaneous treatment of EVOOE 
and mitomycin reduced the chemotherapeutic cytotoxicity. At 
a drug concentration of 100 µg/ml the cell viability increased 
from ~20% when exposed to mitomycin alone to 50% with the 
co‑treatment, and similar behavior was observed at all of the 
concentrations tested. The data showed that EVOOE reduced 
the mitomycin antiproliferative ability without affecting 
PARP‑1 cleavage (Fig. 6B). To clarify the possible involvement 
of ROS inhibition in the decrease of the drug cytotoxicity we 
performed DCF assay and we found that mitomycin at the dose 
of 100 µg/ml strongly increased intracellular ROS production 
in T24 cells (Fig. 6C) whereas the co‑treatment with EVOOE 
strongly reduced the ROS production with a considerable left‑
ward shift of fluorescence.
EVOOE positively affects paclitaxel cytotoxicity. Paclitaxel is 
a mitotic inhibitor isolated from the bark of the Pacific yew 
tree, Taxus brevifolia and is named Taxol. This antineoplastic 
agent is indicated for the treatment of advanced carcinoma of 
the ovary, and other types of cancer including BCa (27). To 
perform our experiments, we treated T24 cells for 24 h with 
three different concentrations of paclitaxel alone or in associa‑
tion with 10 µg/ml of EVOOE. The obtained data are shown 
in Fig. 7A. Importantly, at each tested concentration, the addi‑
tion of EVOOE strongly increased drug cytotoxicity. When 
we treated the cells with 5 nM paclitaxel, the cell viability 
decreased from 75 to ~25% in the presence of the EVOOE, and 
a similar response was observed at 20 and 100 nM. Notably, 
data analysis showed that exposure to 100 nM paclitaxel 
exerted the same cytotoxicity as exposure to 5 nM of the same 
drug when used in association with EVOOE. In order to eval‑
uate the mechanism underlying the increased cell death, we 
performed western blot analyses to assess PARP‑1 cleavage. 
As is clearly evident from Fig. 7B, the simultaneous treat‑
ment of paclitaxel and EVOOE strongly increased the protein 
cleavage at each tested concentration. Moreover the data from 
the DCF assay showed that paclitaxel alone did not induce 
oxidative stress, whereas EVOOE co‑treatment reduced basal 
ROS production (Fig. 7C).
Discussion
The relevance of polyphenols in nutrition and their possible 
role as new drug candidates is well documented by the vast 
Figure 6. EVOOE co‑treatment decreases mitomycin C (Mit.) cytotoxicity without affecting apoptotic cell death in BCa T24 cells. (A) T24 cell viability after 
24 h of exposure to various doses of the chemotherapeutic in the presence or absence of 10 µg/ml EVOOE. Data are presented as means ± SD. ***P<0.001. 
(B) PARP‑1 cleavage after 24 h of treatment of T24 cells as in (A). (C) Histograms representing the mean cell fluorescence which is directly linked to ROS 
content. The straight line indicates the mean fluorescence of the untreated cells. EVOOE, extra‑virgin olive oil extract; BCa, bladder cancer.
COCCIA et al:  OLIVE OIL PHENOLS INDUCE BLADDER CANCER CELL DEATH8
body of literature in recent years. Many studies have evalu‑
ated the effects of these molecules, either as single purified 
compounds or as crude extracts, on various pathophysiological 
processes, in particular as neuroprotective, cardioprotective, 
anti‑inflammatory and anticancer agents.
The antioxidant activity of polyphenols was considered as 
the main mechanism of action of these compounds as anti‑
cancer agents, given the evidence that oxidative stress acts as 
a focal process in cancer development and progression (28). 
However, oxidative stress is only one of the many aspects of 
cancer pathophysiology which is a complex phenomenon and 
implies an alteration of many different signaling pathways not 
strictly related to intracellular redox equilibrium.
In recent years our group has focused on the effect of 
olive oil polyphenolic extracts on various cancer cell cultures, 
in particular on BCa cells. It is well known that after oral 
ingestion, polyphenols are excreted in urine and may reach 
concentrations high enough to exert a biological effect (29,30). 
This phenomenon may explain the reduced incidence of BCa 
evidenced by epidemiological studies (3,6).
Our previous study demonstrated that very low doses 
of total polyphenol extract from olive oil strongly affect 
bladder cell motility through a modulation of metalloprotease 
activity (20). In the present study, we evaluated whether the 
antiproliferative effect of EVOOE can modulate the toxicity of 
chemotherapeutic drugs commonly used in cancer treatment.
First, we evaluated the cell toxicity exerted by EVOOE on 
two different BCa cell lines, T24 and 5637, which are charac‑
terized by two different grades and are widely used as in vitro 
models (31‑33) as they cover the more frequent subtypes of 
BCa. 5637 cells well represent the E2F3/RB1 pathway due to 
amplification of 6p22.3, concomitant with loss of one copy of 
RB1 and mutation of the other copy. The T24 cell line belongs 
to the alternative pathway of FGFR3/CCND1 by mutated 
HRAS and over‑represented CCND1 (34). Viability and 
clonogenic data indicated that T24 cells were more prone to 
the toxic effect of EVOOE compared to 5367 cells, and these 
data were further supported by cell cycle analyses which high‑
lighted that both cell lines were arrested in the G2/M phase but 
with a different mechanism which resulted in apoptotic death 
only for T24 cells, with a consistent increase in the sub‑G1 
peak that was not evidenced in 5637 cells.
The data obtained from cell cycle analysis showed a 
similar mechanism of action of EVOOE, in fact both of the 
cell lines tested were subjected to growth arrest prior to 
mitosis. While performing viability experiments, we observed 
a considerable change in cell morphology, in both T24 and 
5637 cells assuming a rounded shape even after a very short 
treatment. We hence performed immunofluorescence staining 
of the cytoskeletal proteins F‑actin and α‑tubulin which are 
involved in the modulation of cell shape and mitosis. These 
experiments confirmed that after treatment with EVOOE there 
was a marked rearrangement of the cytoskeletal proteins, with 
a perinuclear accumulation of the actin filament. These data 
indicate that the arrest in the G2/M phase could be explained 
by the hampering of normal dynamics of the cytoskeleton and 
of the mitotic fuse. This evidence is in line with the findings of 
Hamdi and Castellon (35) who demonstrated that oleuropein 
treatment disrupted the organization of actin filaments thus 
altering the shape of cancer cells and their ability to proliferate. 
Figure 7. EVOOE co‑treatment strongly increases paclitaxel (PTX)‑induced apoptosis in BCa T24 cells. (A) T24 cell viability after 24 h of exposure to various 
doses of the chemotherapeutic in the presence or absence of 10 µg/ml EVOOE. Data are presented as means ± SD. ***P<0.001. (B) PARP‑1 cleavage after 24 h 
of treatment of T24 cells as in (A). (C) Histograms represent the mean cell fluorescence which is directly linked to ROS content. The straight line indicates the 
mean fluorescence of the untreated cells. EVOOE, extra‑virgin olive oil extract; BCa, bladder cancer.
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These data are also in line with the findings of Monti et al (36), 
who evidenced an interaction between oleocanthal and tau (τ) 
protein, a protein involved in the stabilization of microtubules, 
thereby modulating the plasticity of the cytoskeleton.
Apart from the arrest at the G2/M phase, the two cell 
lines show a different behavior regarding the accumulation 
of sub‑G1 cell fragments, which are indicative of the onset of 
apoptotic processes. In order to evaluate the possible activa‑
tion of apoptotic cell death, we investigated the cleavage 
of PARP‑1 and the protein level of pro‑caspase‑3 and ‑9 
following EVOOE treatment. Data confirmed the activation 
of apoptosis only in the T24 cells and only at high EVOOE 
doses, confirming the cytofluorimetric evidence. This different 
behavior of the two cell lines in response to EVOOE treat‑
ment, can be explained by the different mutational status in 
various key genes involved in cell proliferation regulation (34). 
The induction of programmed cell death only in T24 can also 
explain the different susceptibility to the cytotoxic action of 
EVOOE, as demonstrated by the difference in the decrease in 
viability observed in our experiments (Fig. 1).
A wide body of literature indicates that apoptosis may be 
responsible for polyphenol‑mediated cell death. This effect 
has been attributed to ROS production induced by polyphe‑
nols in certain experimental conditions (37,38). To clarify 
whether EVOOE may induce oxidative stress thus leading to 
apoptosis, we evaluated intracellular ROS production via a 
cytofluorimetric assay. Our data indicated that EVOOE was 
able to decrease the basal level of oxidative stress in the T24 
cells and to a lower extent also in the 5637 cells. Hence, in our 
model the induction of apoptosis was not due to ROS produc‑
tion but had to be attributed to other molecular mechanisms 
such as the inhibition of pro‑survival cell signaling path‑
ways (37). In the last part of this study we evaluated the ability 
of low concentrations of EVOOE to improve the activity of 
different chemotherapeutics used in common clinical prac‑
tice. It is of great interest to underline that current therapy 
in the management of BCa consists of bladder instillation of 
alchilant agents (39) that on the other hand exert unfavorable 
effects (40). In the present study we used an approach based 
on the comparison of viability since one of the two treatments 
given in co‑association was always non‑toxic (EVOOE up to 
10 µg/ml). As expected, we obtained different results based 
on the drug tested. Our data demonstrated that simultaneous 
treatment with mitomycin and EVOOE markedly decreased 
the cytotoxicity of the chemotherapeutic. These results are 
surprising only in part because it is well known that mito‑
mycin exerts its toxic effect through the induction of oxidative 
stress and the antioxidant activity of the phenolic molecules 
may dampen its efficacy.
Conversely to what was observed for mitomycin, the 
addition of EVOOE to the paclitaxel treatment led to a strong 
increase in the drug toxicity with a marked induction of apop‑
totic cell death. These data are of great interest since the dose 
of EVOOE used for this experiment was non‑toxic per se to 
the cells themselves, and this indicates a synergic effect in 
combination with paclitaxel. It can be hypothesized that the 
cytotoxicity enhancement of paclitaxel could be attributed 
to the alteration in gene expression occurring at low doses 
of phenolic extract, as observed in our previous study (20), 
that chemosensitize the cells by altering pathways involved 
in cell growth and proliferation such as platelet‑activating 
factor (PAF) receptor signaling or PI3K signaling (37,41,42).
There are controversial data concerning the role of antioxi‑
dant supplements during chemotherapy (43‑45), however it is 
generally recommended to avoid the use of antioxidant food 
supplements and herbal products. Based on our experimental 
results, the polyphenolic extracts could be developed as poten‑
tial adjuvants in combination with certain chemotherapeutic 
drugs which do not exert cytotoxicity through the induction of 
oxidative stress.
Collectively, our findings suggest that the potential adjuvant 
properties of EVOO phenols are related to the class of drugs 
used according to previously published data that point out how 
the adjunct of high doses of an antioxidant to chemotherapy 
does not always improve the pharmacological treatment (46). 
It is important to highlight that even if the mechanism of action 
of many chemotherapeutics and also radiotherapy is based in 
part on the production of free radicals (44,45) there are also 
cytostatic drugs that do not exert their effects through oxida‑
tive stress mechanisms such as paclitaxel, vinca alkaloids, 
anthracycline and many others that can be improved by the 
use of antioxidant‑rich supplements (43).
In conclusion, our data demonstrated that the combination 
of EVOOE and paclitaxel exhibited a markedly higher antip‑
roliferative activity in vitro compared with each of these alone. 
To the best of our knowledge this is the first report that demon‑
strates how EVOO phenols markedly improve the activity of 
paclitaxel, and this evidence may pave the way for the study of 
new therapeutic strategies which exploit the synergy between 
drugs and nutraceuticals.
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